FDA Discovers Slew Of Quality Issues At Amylin Plant
A U.S. Food and Drug Administration inspection of the Amylin Pharmaceuticals Inc. factory responsible for manufacturing certain formulations of its blockbuster diabetes drug Byetta has revealed a number of quality control...To view the full article, register now.
Already a subscriber? Click here to view full article